Table of Content

1. Introduction To Cancer Vaccines


2. Mechanism Of Cancer Vaccines
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism


3. Global Cancer Vaccine Market Overview
3.1 Current Market Scenario
3.2 Future Market Opportunity


4. Global Cancer Vaccine Market Trends By Country
4.1 US
4.2 Europe
4.3 China
4.4 Japan
4.5 India
4.6 South Korea
4.7 Australia
4.8 South America
4.9 Canada
4.10 UK


5. Cancer Vaccine Market Insight & Proprietary Vaccine Manufacturing Technologies By Indication
5.1 Lung Cancer
5.1.1 Current Clinical Market Trends
5.1.2 Proprietary Manufacturing Technology Platforms

5.2 Pancreatic Cancer
5.2.1 Current Clinical Market Trends
5.2.2 Proprietary Manufacturing Technology Platforms

5.3 Prostate Cancer
5.3.1 Current Clinical Market Trends
5.3.2 Proprietary Manufacturing Technology Platforms

5.4 Bladder Cancer
5.4.1 Current Clinical Market Trends
5.4.2 Proprietary Manufacturing Technology Platforms

5.5 Melanoma
5.5.1 Current Clinical Market Trends
5.5.2 Proprietary Manufacturing Technology Platforms

5.6 Breast Cancer
5.6.1 Current Clinical Market Trends
5.6.2 Proprietary Manufacturing Technology Platforms

5.7 Colorectal Cancer
5.7.1 Current Clinical Market Trends
5.7.2 Proprietary Manufacturing Technology Platforms

5.8 Glioblastoma
5.8.1 Current Clinical Market Trends
5.8.2 Proprietary Manufacturing Technology Platforms

5.9 Ovarian Cancer
5.9.1 Current Clinical Market Trends
5.9.2 Proprietary Manufacturing Technology Platforms

5.10 Human papillomavirus Associated Cancer
5.10.1 Current Clinical Market Trends



6. Approved Cancer Vaccines – Price & Dosage Analysis
6.1 Gardasil/ Gardasil 9
6.2 Cervarix
6.3 Heplisav-B
6.4 PreHevbrio
6.5 Engerix-B
6.6 Twinrix
6.7 Recombivax HB
6.8 Provenge
6.9 Cecolin
6.10 CimaVax
6.11 Vaxira
6.12 Riavax
6.13 Oncophage
6.14 Mycidac-C
6.15 Reniale
6.16 Cervavac*


7. Global Cancer Vaccines Clinical Trials Overview
7.1 By Company
7.2 By Country
7.3 By Indication
7.4 By Patient Segment/Disease Stage
7.5 By Phase


8. Global Cancer Vaccines Clinical Trials By Company, Country, Indication & Phase
8.1 Research
8.2 Preclinical
8.3 Phase-I
8.4 Phase-I/II
8.5 Phase-II
8.6 Phase-II/III
8.7 Phase-III
8.8 Registered


9. Marketed Cancer Vaccines Clinical Insight By Company, Country &Indication


10. Competitve Landscape
10.1 Ayala Pharmaceuticals
10.2 BioNTech
10.3 CureVac
10.4 Elicio Therapeutics
10.5 Enochian BioSciences
10.6 Enterome
10.7 EpiThany
10.8 Gradalis
10.9 Hookipa Pharma
10.10 Immunitor
10.11 Immunomic Therapeutics
10.12 In3Bio
10.13 IO Biotech
10.14 ISA Pharmaceuticals
10.15 Jiangsu Recbio Technology
10.16 Mary Crowley Cancer Research Center
10.17 Mayo Clinic
10.18 Memorial Sloan-Kettering Cancer Center
10.19 Mendus
10.20 Merck
10.21 MGFB Bio
10.22 Nykode Therapeutics
10.23 OncoTherapy Science
10.24 pHion Therapeutics
10.25 Qu Biologics
10.26 Scancell
10.27 UbiVac
10.28 Vaccitech
10.29 VAXIMM
10.30 Zhongsheng Kangyuan Biotechnology



List of Tables

Figure 4-1: US - Ongoing Cancer Vaccines Clinical Trials
Figure 4-2: EMA - Approved Cancer Vaccines
Figure 4-3: Europe - Cancer Vaccines Currently Under Clinical Trial
Figure 4-4: China – NMPA Approved Human Papillomavirus Vaccines
Figure 4-5: Japan - Merck Held Clinical Trials
Figure 4-6: South Korea – Ongoing Cancer Vaccines Clinical Trials
Figure 4-7: Australia – TGA Approved Hepatitis-B Vaccines
Figure 4-8: Australia – TGA Approved Human Papillomavirus Vaccines
Figure 4-9: Australia – Ongoing Melanoma Vaccines Clinical Trials
Figure 4-10: South America - Cancer Vaccines Currently Under Clinical Trial
Figure 4-11: Canada - Approved Cancer Vaccines
Figure 4-12: Canada - Cancer Vaccines Currently Under Clinical Trial
Figure 4-13: UK - Approved Cancer Vaccines
Figure 4-14: UK - Cancer Vaccines Currently Under Clinical Trial